Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Change in Accured Expenses (2020 - 2025)

Maxcyte (MXCT) has disclosed Change in Accured Expenses for 6 consecutive years, with -$383000.0 as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses rose 17.28% to -$383000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$3.7 million through Dec 2025, down 97.61% year-over-year, with the annual reading at -$3.7 million for FY2025, 97.61% down from the prior year.
  • Change in Accured Expenses for Q4 2025 was -$383000.0 at Maxcyte, up from -$3.3 million in the prior quarter.
  • The five-year high for Change in Accured Expenses was $2.6 million in Q3 2023, with the low at -$3.3 million in Q3 2025.
  • Average Change in Accured Expenses over 5 years is -$77725.0, with a median of -$4000.0 recorded in 2024.
  • Peak annual rise in Change in Accured Expenses hit 136233.33% in 2023, while the deepest fall reached 341.32% in 2023.
  • Over 5 years, Change in Accured Expenses stood at $357850.0 in 2021, then soared by 172.91% to $976600.0 in 2022, then soared by 77.35% to $1.7 million in 2023, then plummeted by 126.73% to -$463000.0 in 2024, then grew by 17.28% to -$383000.0 in 2025.
  • According to Business Quant data, Change in Accured Expenses over the past three periods came in at -$383000.0, -$3.3 million, and -$22000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.